Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vanda Pharmaceuticals

4.53
+0.04000.89%
Volume:242.33K
Turnover:1.11M
Market Cap:266.97M
PE:-5.95
High:4.63
Open:4.50
Low:4.50
Close:4.49
Loading ...

Director Stephen Ray Mitchell Reports Disposal of Vanda Pharmaceuticals Inc. Common Shares

Reuters
·
17 Jun

Vanda Pharmaceuticals Initiates First-in-Human Trial of VCA-894A for Rare Charcot-Marie-Tooth Disease Type 2S

Reuters
·
10 Jun

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating Vca-894a in Charcot-Marie-Tooth Disease Type 2S

THOMSON REUTERS
·
10 Jun

Vanda Pharmaceuticals Inc. Held Annual Stockholders Meeting

Reuters
·
06 Jun

Vanda Pharmaceuticals' President and CEO, Mihael Hristos Polymeropoulos, Reports Acquisition of Common Shares

Reuters
·
20 May

Vanda Pharmaceuticals Inc. to Participate in Mizuho Neuro & Ophthalmology Summit 2025

Reuters
·
17 May

Vanda Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
14 May

Vanda Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Vanda Pharma Q1 GAAP EPS $(0.50) Beats $(0.60) Estimate, Sales $50.04M Beat $45.13M Estimate

Benzinga
·
08 May

BRIEF-Vanda Pharmaceuticals Q1 EPS USD -0.5

Reuters
·
08 May

Vanda Pharmaceuticals Inc: Reiterating Its 2025 Total Revenues Guidance

THOMSON REUTERS
·
08 May

Vanda Pharmaceuticals Q1 Operating Expenses USD 91.069 Million

THOMSON REUTERS
·
08 May

Vanda Pharmaceuticals Q1 EPS USD -0.5

THOMSON REUTERS
·
08 May

Vanda Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
07 May

Vanda (VNDA) Receives a Buy from H.C. Wainwright

TIPRANKS
·
07 May

Vanda Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters
·
06 May

Vanda Pharmaceuticals Says FDA Accepts Bysanti Application for Bipolar I, Schizophrenia

MT Newswires Live
·
05 May

BRIEF-Drugmaker Vanda Announces Bysanti NDA Filing

Reuters
·
05 May

Vanda Pharmaceuticals Inc - Bysanti Eligible for 5-Year Regulatory Data Exclusivity IF Approved

THOMSON REUTERS
·
05 May

Vanda Pharmaceuticals Inc - FDA Decision on Bysanti Nda Expected by February 21, 2026

THOMSON REUTERS
·
05 May